Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

GlobeNewsWire • Sep 1, 2026

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor's presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

GlobeNewsWire • Jul 30, 2026

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™).

GlobeNewsWire • Jul 7, 2026

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

New Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor.

GlobeNewsWire • Jun 2, 2026

Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis

Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring'26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.

GlobeNewsWire • Apr 28, 2026

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor's state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management.

GlobeNewsWire • Apr 8, 2026

Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater.

GlobeNewsWire • Mar 26, 2026

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA).

GlobeNewsWire • Mar 17, 2026

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Seeking Alpha • Mar 10, 2026

Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings.

GlobeNewsWire • Mar 10, 2026